Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid

1. A solid form of Compound 1:

wherein said solid form is selected from the group consisting of:

(1) Solid Form D of Compound 1, wherein said Solid Form D has: an X-ray powder diffraction pattern comprising peaks at 7.9, 14.4, 14.8, 15.9, and 23.9±0.2° 2θ; an X-ray powder diffraction pattern comprising peaks at 5.9, 11.8, 16.8, 24.1, and 26.9±0.2° 2θ; an X-ray powder diffraction pattern comprising peaks at 6.6, 7.9, 13.4, 15.9, 20.1, and 24.5±0.2° 2θ; or an X-ray powder diffraction pattern substantially in accordance with FIG. 1 ;

(2) Solid Form E of Compound 1, wherein said Solid Form E has: an X-ray powder diffraction pattern comprising peaks at 21.3, 22.8, 23.7, 27.0, and 27.7±0.2° 2θ; an X-ray powder diffraction pattern comprising peaks at 16.4, 22.8, 23.6, 27.0, and 27.7±0.2° 2θ; or an X-ray powder diffraction pattern substantially in accordance with FIG. 4 ;

(3) Solid Form F of Compound 1, wherein said Solid Form F has: an X-ray powder diffraction pattern comprising peaks at 8.5, 15.3, 18.5, 21.3, and 22.5±0.2° 2θ; an X-ray powder diffraction pattern comprising peaks at 4.2, 12.7, 19.5, 25.9, and 29.9±0.2° 2θ; an X-ray powder diffraction pattern comprising peaks at 4.2, 8.5, 15.3, 18.5, 21.3, and 22.5±0.2° 2θ; or an X-ray powder diffraction pattern substantially in accordance with FIG. 7 ;

(4) Solid Form H B of Compound 1, wherein said Solid Form H B has: an X-ray powder diffraction pattern comprising peaks at 14.6, 15.3, 18.5, 20.4, and 28.1±0.2° 2θ; an X-ray powder diffraction pattern comprising peaks at 16.0, 20.4, 26.8, 28.1, and 29.6±0.2° 2θ; an X-ray powder diffraction pattern comprising peaks at 7.9, 14.6, 16.0, 17.6, and 28.1±0.2° 2θ; or an X-ray powder diffraction pattern substantially in accordance with FIG. 13 ;

(5) Solid Form S A of Compound 1, wherein said Solid Form S A has: an X-ray powder diffraction pattern comprising peaks at 13.1, 17.5, 19.1, 22.7, and 24.6±0.2° 2θ; an X-ray powder diffraction pattern comprising peaks at 13.1, 17.5, 19.1, 32.0, and 35.3±0.2° 2θ; an X-ray powder diffraction pattern comprising peaks at 13.1, 17.5, 19.1, 24.6, and 32.0±0.2° 2θ; or an X-ray powder diffraction pattern substantially in accordance with FIG. 16 ;

(6) Solid Form S B of Compound 1, wherein said Solid Form S B has: an X-ray powder diffraction pattern comprising peaks at 14.0, 19.6, 20.0, 22.0, and 28.5±0.2° 2θ; an X-ray powder diffraction pattern comprising peaks at 14.0, 19.6, 20.0, 31.5, and 33.6±0.2° 2θ; an X-ray powder diffraction pattern comprising peaks at 6.8, 14.0, 17.3, 19.6, 20.0, and 28.5±0.2° 2θ; or an X-ray powder diffraction pattern substantially in accordance with FIG. 19 ;

(7) Solid Form S C of Compound 1, wherein said Solid Form S C has: an X-ray powder diffraction pattern comprising peaks at 11.0, 15.1, 18.6, 22.1, and 26.4±0.2° 2θ; an X-ray powder diffraction pattern comprising peaks at 4.8, 9.5, 11.0, 21.8, and 34.8±0.2° 2θ; an X-ray powder diffraction pattern comprising peaks at 4.8, 7.9, 14.3, 18.6, 21.1, and 22.1±0.2° 2θ; or an X-ray powder diffraction pattern substantially in accordance with FIG. 24 ;

(8) Solid Form S D of Compound 1, wherein said Solid Form S D has: an X-ray powder diffraction pattern comprising peaks at 17.0, 24.0, 25.5, 26.2 and 28.4±0.2° 2θ; an X-ray powder diffraction pattern comprising peaks at 12.1, 14.5, 25.5, 29.2, and 36.2±0.2° 2θ; an X-ray powder diffraction pattern comprising peaks at 12.1, 17.0, 24.0, 25.5, and 26.2±0.2° 2θ; or an X-ray powder diffraction pattern substantially in accordance with FIG. 25 ;

(9) Solid Form S E of Compound 1, wherein said Solid Form S E has: an X-ray powder diffraction pattern comprising peaks at 15.8, 17.0, 24.6, 26.5, and 27.2±0.2° 2θ; an X-ray powder diffraction pattern comprising peaks at 14.5, 17.0, 25.1, 26.5, and 27.2±0.2° 2θ; an X-ray powder diffraction pattern comprising peaks at 14.5, 15.8, 22.4, 24.6, 26.5, and 27.2±0.2° 2θ; or an X-ray powder diffraction pattern substantially in accordance with FIG. 28 ; and

(10) Solid Form S F of Compound 1, wherein said Solid Form S F has: an X-ray powder diffraction pattern comprising peaks at 5.9, 11.8, 24.1, 24.3, and 26.2±0.2° 2θ; an X-ray powder diffraction pattern comprising peaks at 5.9, 11.8, 16.8, 24.1, and 26.9±0.2° 2θ; an X-ray powder diffraction pattern comprising peaks at 5.9, 11.8, 16.8, 24.3, 26.2, and 26.9±0.2° 2θ; or an X-ray powder diffraction pattern substantially in accordance with FIG. 31 .

2. The solid form of claim 1 , wherein said solid form is Solid Form D of Compound 1,

wherein said Solid Form D has: an X-ray powder diffraction pattern comprising peaks at 7.9, 14.4, 14.8, 15.9, and 23.9±0.2° 2θ; an X-ray powder diffraction pattern comprising peaks at 5.9, 11.8, 16.8, 24.1, and 26.9±0.2° 2θ; an X-ray powder diffraction pattern comprising peaks at 6.6, 7.9, 13.4, 15.9, 20.1, and 24.5±0.2° 2θ; or an X-ray powder diffraction pattern substantially in accordance with FIG. 1 .

3. A pharmaceutical composition comprising the solid form of claim 1 .

4. An oral dosage form comprising the solid form of claim 1 .

5. A method of preparing the solid form of claim 1 , wherein said solid form is solid Form D of Compound 1,

comprising:

a) preparing a solution of Compound 1 in methanol or methanol/water;

b) bringing the solution to super-saturation to cause formation of solid Form D of Compound 1; and

c) isolating solid Form D of Compound 1.

6. The solid form of claim 1 , wherein said solid form is Solid Form E of Compound 1,

wherein said Solid Form E has: an X-ray powder diffraction pattern comprising peaks at 21.3, 22.8, 23.7, 27.0, and 27.7±0.2° 2θ; an X-ray powder diffraction pattern comprising peaks at 16.4, 22.8, 23.6, 27.0, and 27.7±0.2° 2θ; or an X-ray powder diffraction pattern substantially in accordance with FIG. 4 .

7. A method of preparing the solid form of claim 1 , wherein said solid form is solid Form E of Compound 1,

comprising:

a) preparing a solution of Compound 1 in tetrahydrofuran or methyl ethyl ketone;

b) bringing the solution to super-saturation to cause formation of solid Form E of Compound 1; and

c) isolating solid Form E of Compound 1.

8. The solid form of claim 1 , wherein said solid form is Solid Form F of Compound 1,

wherein said Solid Form F has: an X-ray powder diffraction pattern comprising peaks at 8.5, 15.3, 18.5, 21.3, and 22.5±0.2° 2θ; an X-ray powder diffraction pattern comprising peaks at 4.2, 12.7, 19.5, 25.9, and 29.9±0.2° 2θ or at 4.2, 8.5, 15.3, 18.5, 21.3, and 22.5±0.2° 2θ; or an X-ray powder diffraction pattern substantially in accordance with FIG. 7 .

9. A method of preparing the solid form of claim 1 , wherein said solid form is solid Form F of Compound 1,

comprising:

a) preparing a solution of Compound 1 in ethanol/water;

b) bringing the solution to super-saturation to cause formation of solid Form F of Compound 1; and

c) isolating solid Form F of Compound 1.

10. The solid form of claim 1 , wherein said solid form is Solid Form H B of Compound 1,

wherein said Solid Form H B has: an X-ray powder diffraction pattern comprising peaks at 14.6, 15.3, 18.5, 20.4, and 28.1±0.2° 2θ; an X-ray powder diffraction pattern comprising peaks at 16.0, 20.4, 26.8, 28.1, and 29.6±0.2° 2θ an X-ray powder diffraction pattern comprising peaks at 7.9, 14.6, 16.0, 17.6, and 28.1±0.2° 2θ; or an X-ray powder diffraction pattern substantially in accordance with FIG. 13 .

11. A method of preparing the solid form of claim 1 , wherein said solid form is Solid Form H B of Compound 1,

comprising:

a) preparing a solution of Compound 1 in methanol;

b) bringing the solution to super-saturation to cause formation of solid Form H B of Compound 1; and

c) isolating solid Form H B of Compound 1.

12. The solid form of claim 1 , wherein said solid form is Solid Form S A of Compound 1,

wherein said Solid Form S A has: an X-ray powder diffraction pattern comprising peaks at 13.1, 17.5, 19.1, 22.7, and 24.6±0.2° 2θ; an X-ray powder diffraction pattern comprising peaks at 13.1, 17.5, 19.1, 32.0, and 35.3±0.2° 2θ; an X-ray powder diffraction pattern comprising peaks at 13.1, 17.5, 19.1, 24.6, and 32.0±0.2° 2θ; or an X-ray powder diffraction pattern substantially in accordance with FIG. 16 .

13. A method of preparing the solid form of claim 1 , wherein said solid form is solid Form S A , S b , or S c of Compound 1,

comprising:

a) preparing a solution of Compound 1 in 1,4-dioxane;

b) bringing the solution to super-saturation to cause formation of solid Form S A , S b , or S c of Compound 1; and

c) isolating solid Form S A , S b , or S c of Compound 1.

14. The solid form of claim 1 , wherein said solid form is Solid Form S B of Compound 1,

wherein said Solid Form S B has: an X-ray powder diffraction pattern comprising peaks at 14.0, 19.6, 20.0, 22.0, and 28.5±0.2° 2θ; an X-ray powder diffraction pattern comprising peaks at 14.0, 19.6, 20.0, 31.5, and 33.6±0.2° 2θ; an X-ray powder diffraction pattern comprising peaks at 6.8, 14.0, 17.3, 19.6, 20.0, and 28.5±0.2° 2θ; or an X-ray powder diffraction pattern substantially in accordance with FIG. 19 .

15. The solid form of claim 1 , wherein said solid form is Solid Form S C of Compound 1,

wherein said Solid Form S C has: an X-ray powder diffraction pattern comprising peaks at 11.0, 15.1, 18.6, 22.1, and 26.4±0.2° 2θ; an X-ray powder diffraction pattern comprising peaks at 4.8, 9.5, 11.0, 21.8, and 34.8±0.2° 2θ; an X-ray powder diffraction pattern comprising peaks at 4.8, 7.9, 14.3, 18.6, 21.1, and 22.1±0.2° 2θ; or an X-ray powder diffraction pattern substantially in accordance with FIG. 24 .

16. The solid form of claim 1 , wherein said solid form is Solid Form S D of Compound 1,

wherein said Solid Form S D has: an X-ray powder diffraction pattern comprising peaks at 17.0, 24.0, 25.5, 26.2 and 28.4±0.2° 2θ; an X-ray powder diffraction pattern comprising peaks at 12.1, 14.5, 25.5, 29.2, and 36.2±0.2° 2θ; an X-ray powder diffraction pattern comprising peaks at 12.1, 17.0, 24.0, 25.5, and 26.2±0.2° 2θ; or an X-ray powder diffraction pattern substantially in accordance with FIG. 25 .

17. A method of preparing the solid form of claim 1 , wherein said solid form is solid Form S D of Compound 1,

comprising:

a) preparing a solution of Compound 1 in anisole;

b) bringing the solution to super-saturation to cause formation of solid Form S D of Compound 1; and

c) isolating solid Form S D of Compound 1.

18. The solid form of claim 1 , wherein said solid form is Solid Form S E of Compound 1,

wherein said Solid Form S E has: an X-ray powder diffraction pattern comprising peaks at 15.8, 17.0, 24.6, 26.5, and 27.2±0.2° 2θ; an X-ray powder diffraction pattern comprising peaks at 14.5, 17.0, 25.1, 26.5, and 27.2±0.2° 2θ; an X-ray powder diffraction pattern comprising peaks at 14.5, 15.8, 22.4, 24.6, 26.5, and 27.2±0.2° 2θ; or an X-ray powder diffraction pattern substantially in accordance with FIG. 28 .

19. A method of preparing the solid form of claim 1 , wherein said solid form is solid Form S E or S F of Compound 1,

comprising:

a) preparing a solution of Compound 1 in dimethylacetamide;

b) bringing the solution to super-saturation to cause formation of solid Form S E or S F of Compound 1; and

c) isolating solid Form S E or S F of Compound 1.

20. The solid form of claim 1 , wherein said solid form is Solid Form S F of Compound 1,

wherein said Solid Form S F has: an X-ray powder diffraction pattern comprising peaks at 5.9, 11.8, 24.1, 24.3, and 26.2±0.2° 2θ; an X-ray powder diffraction pattern comprising peaks at 5.9, 11.8, 16.8, 24.1, and 26.9±0.2° 2θ; an X-ray powder diffraction pattern comprising peaks at 5.9, 11.8, 16.8, 24.3, 26.2, and 26.9±0.2° 2θ; or an X-ray powder diffraction pattern substantially in accordance with FIG. 31 .